Please login to the form below

Exelixis

This page shows the latest Exelixis news and features for those working in and with pharma, biotech and healthcare.

with Exelixis/Ipsen’s multikinase inhibitor Cabometyx (cabozantinib).

Merck’s Bavencio joins first-line kidney cancer face-off

Both combinations could challenge the position of Bristol-Myers Squibb’s Opdivo (nivolumab) and Yervoy (ipilimumab), which has started to replace Sutent and other TKIs like Exelixis’ Cabometyx (cabozantinib) as the ... Exelixis’ drug could also be
Daily Brief: Amgen offers Repatha deals in Europe, will Persephone slash Herceptin use?

EUROPE. European approval for Cabometyx in RCC. The European Commission has approved Ipsen and Exelixis’ Cabometyx for the first-line treatment of adults with advanced renal cell carcinoma (RCC).
Pfizer’s plans for Inlyta go awry with failed adjuvant trial

nivolumab) and Exelixis’ multikinase inhibitor Cabometyx (cabozantinib) - backed by strong overall survival data - as well as Eisai’s multikinase drug Lenvima (lenvatinib).
FDA’s year-end approvals take annual tally to 46

The closing few days of 2017 also saw line extension approvals for Exelixis and Novartis. ... therapy. Analysts at Leerink have suggested the new indication could catapult Exelixis’ cabozantinib franchise to $1bn in sales in 2025.
Ipsen’s liver cancer treatment clears phase III trial

Cabometyx on track for new liver cancer indication. Ipsen and partner Exelixis are on track to file cancer treatment Cabometyx (cabozantinib) for a new liver cancer indication in the first half

More from news
Approximately 4 fully matching, plus 21 partially matching documents found.

Charting a course for expansion

Cabometyx accelerates. Earlier this year Ipsen signed another deal to bolster its pipeline by harnessing external innovation, licensing promising cancer drug Cabometyx (cabozantinib) from Californian biotech Exelixis.
Deal Watch March 2016

Two deals involved products at a later stage of development: Dr Reddy's licence for Xenoport's phase II product XP23829 for plaque psoriasis, and Ipsen's licence for Exelixis's ... Collaboration – discovery, development &commercialisation. $965.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Exelixis appoints Andrew Peters to newly created position

He joins the biotech as its vice president, strategy. California, US-based biotechnology group Exelixis has appointed Andrew Peters as vice president of strategy. ... His familiarity with Exelixis and the biotech landscape should make for a seamless
Decibel Therapeutics expands leadership team

Prior to this, he was president and chief executive of Exelixis and served as president of Bayer Biotechnology, overseeing the business development, manufacturing and R&D of the company's biological
Frances Heller joins BMS senior management

Heller comes to BMS from Exelixis, a San Francisco-based genomics drug discovery company, where she was executive vice president of business development.

More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Account Manager– Medical Communications: (Negotiable - depending on experience)

Director of Scientific Services, Medical Communications, Six fig...: Six figure salary

Principal Medical Writer: £48 - 58, 000 according to skills and experience benefits

Add my company

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

How do companies prepare for reimbursement?: Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
Integrating electronic health records into clinical trials: How organisations are working to realise the research potential of EHRs...
Keeping up the fight against HIV and using the lessons to tackle other threats: Danny Buckland interviews Gilead’s Mike Elliott...